Conduit Pharmaceuticals Bolsa (NASDAQ: CDT)

Últimas noticias sobre Conduit Pharmaceuticals (NASDAQ:CDT) Bolsa

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

Award-winning Black Hornet unmanned aerial system is deployed in more than 45 countries

Teledyne FLIR's Black Hornet 4 Nano-Drone Approved For Blue UAS List Following NDAA And Cybersecurity Verification

Forte Biosciences, Inc. (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54280591&amp;newsitemid=20250623454480&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=ea891ed7d5d480fe423068ec390705f6">www.fortebiorx.com</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101).
The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call.
Please connect to the call using the following link: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Flifescievents.com%2Fevent%2Fjgs927tsivn4w038%2F&amp;esheet=54280591&amp;newsitemid=20250623454480&amp;lan=en-US&amp;anchor=https%3A%2F%2Flifescievents.com%2Fevent%2Fjgs927tsivn4w038%2F&amp;index=2&amp;md5=6522294948f67a8efcb35580dba86ff5">https://lifescievents.com/event/jgs927tsivn4w038/</a>. The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fortebiorx.com%2Finvestor-relations%2Fdefault.aspx&amp;esheet=54280591&amp;newsitemid=20250623454480&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.fortebiorx.com%2Finvestor-relations%2Fdefault.aspx&amp;index=3&amp;md5=5175b703811fc969ec4f1fc33724ee33">https://www.fortebiorx.com/investor-relations/default.aspx</a>. An archived webcast will be available on the company's website following the event.
The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms.
FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099).
The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects.
The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo.
Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject).
There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm.
"We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026." said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. "These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026."

FBRX

Forte Biosciences Reports Results in Celiac Disease Trial, Paving Way for Phase 2 in 2026

<ul>
<li>$2.2 million gross proceeds from warrant inducement transaction</li>
<li>$2.6 million gross proceeds from additional warrant exercises</li>
</ul>
MIAMI, June 23, 2025 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454291-1&amp;h=3593078241&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Finnovative-eyewear-inc-announces-exercise-of-warrants-302236683.html%23financial-modal&amp;a=LUCY">LUCY</a>), the manufacturer of smart eyewear under the Lucyd&#xAE;, Lucyd Armor&#xAE;, Reebok&#xAE;, Eddie Bauer&#xAE; and Nautica&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 746,782&nbsp;shares of the Company's common stock originally issued by the Company on April 14, 2025, at the current exercise price of&nbsp;$2.60&nbsp;per share. The closing of the warrant inducement transaction is expected to occur on or about&nbsp;June 24, 2025, subject to satisfaction of customary closing conditions. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-287142).
The gross proceeds to the Company from the exercise of the warrants in the warrant inducement transaction are expected to be approximately&nbsp;$2.2 million, prior to deducting placement agent fees and offering expenses. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.
In addition, over the last 30 days the Company has received aggregate gross proceeds of approximately $2.6 million from the exercise of certain warrants in the ordinary course by investors. Such investors exercised warrants to purchase an aggregate of 986,532 shares of the Company's common stock originally issued by the Company on April 14, 2025, at the original exercise price of $2.60 per share.

LUCY

Innovative Eyewear Enters Into Definitive Agreements For Immediate Exercise Of 746,782 Warrants At $2.60 Per Share

JP Morgan analyst Michael Mueller downgrades Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Neutral to Underweight and lowers the price target from $55 to $50.

Downgrades

Price Target

Analyst Ratings

LINE

JP Morgan Downgrades Lineage to Underweight, Lowers Price Target to $50

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>, "Telix", "the Company") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix&#xAE; (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting.
The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for Pluvicto&#xAE;2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy3. With RLT now approved for use earlier in the patient journey, the clinical utilization of Illuccix&#xAE; is expected to increase by at least 20,000 scans annually4.
Scott T. Tagawa, MD, a genitourinary (GU) oncologist in New York said, "It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer."
Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, said, "We're pleased that the U.S. label for Illuccix has been expanded to support patient selection for RLT in the pre-taxane setting, aligning with the evolving treatment landscape. PSMA-PET imaging has become a standard of care in the detection and management of prostate cancer. With this update, patients can now benefit from the high diagnostic accuracy of Illuccix to identify those most likely to respond to PSMA-targeted therapy, even earlier in their treatment journey."

Government

Regulations

Telix Wins US Approval to Broaden Illuccix Use, Paving Way for 20,000 More Prostate Cancer Scans Annually

SMTK

Smartkem Expands IP Portfolio With New MicroLED Display Patent That Reduces Material Waste And Enhances Process Efficiency

U.S. stocks settled mixed on Friday, with the S&amp;P 500 falling for the third straight session amid escalating Iran-Israel conflict. For the week, the S&amp;P 500 fell around 0.2%, while the 30-stock Dow gained 0.02%.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: William Stein
<ul class="wp-block-list">
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Hold rating on Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) and raised the price target from $52 to $64 on June 18. This analyst sees around 7% downside in the stock.</li>
<li>Recent News: On May 29, Microchip Technology raised its first-quarter guidance.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Outperform rating on Builders FirstSource, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NASDAQ">BLDR</a>) and cut the price target from $190 to $145 on June 20. This analyst sees around 27% surge in the stock.</li>
<li>Recent News: On June 2, Builders FirstSource named Gayatri Narayan to the newly created role of President, Technology and Digital Solutions.</li>
</ul>
Analyst: Aaron Rakers 
<ul class="wp-block-list">
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and boosted the price target from $130 to $150 on June 20. This analyst sees around 22% upside in the stock.</li>
<li>Recent News: Micron and the Trump Administration announced on June 12 that Micron plans to expand its U.S. investments to approximately $150 billion in domestic memory manufacturing and $50 billion in R&amp;D, potentially creating 90,000 direct and indirect jobs.</li>
</ul>
Analyst: Andrew Kaplowitz
<ul class="wp-block-list">
<li>Analyst Firm: Citigroup</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained a Buy rating on Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) and increased the price target from $98 to $130 on June 16. This analyst sees around 10% upside in the stock.</li>
<li>Recent News: On June 3, Vertiv announced that Mike Giresi will join the company on June 30 as global Chief Information Officer (CIO).</li>
</ul>
Analyst: Alex Rygiel
<ul class="wp-block-list">
<li>Analyst Firm: Texas Capital Securities</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Initiated coverage on LGI Homes, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) with a Hold rating and a price target of $56 on June 17. This analyst sees around 17% upside in the stock.</li>
<li>Recent News: On April 29, LGI Homes posted downbeat quarterly earnings.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

BLDR

LGIH

MCHP

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

Stephens &amp; Co. analyst Jim Salera maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and raises the price target from $200 to $212.

Stephens & Co. Maintains Equal-Weight on Darden Restaurants, Raises Price Target to $212

UTHR

United Therapeutics Completes Enrollment Of ADVANCE OUTCOMES Phase 3 Study For Ralinepag, A Once-Daily Oral PAH Therapy

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Campbell&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>)</h3>
<ul class="wp-block-list">
<li>On June 2, the company reported third-quarter sales growth of 4% year over year (Y/Y) to $2.475 billion, beating the analyst consensus estimate of $2.43 billion. Campbell's CEO Mick Beekhuizen said, "In Meals &amp; Beverages, we are seeing improved consumption across all consumer income groups." The company's stock fell around 4% over the past five days and has a 52-week low of $31.58.</li>
<li>RSI Value: 26.9</li>
<li>CPB Price Action: Shares of Campbell&#8217;s fell 0.03% to close at $31.84 on Friday.</li>
<li>Edge Stock Ratings: 16.9442 Momentum score with Value at 40.23. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cpb"><img loading="lazy" decoding="async" width="421" height="167" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040053/image-323.png" alt="" class="wp-image-957673" style="width:315px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040053/image-323.png 421w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040053/image-323-300x119.png 300w" sizes="(max-width: 421px) 100vw, 421px" /></a></figure>
<h3 class="wp-block-heading">Westrock Coffee Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>)&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 8, Westrock Coffee posted a wider-than-expected quarterly loss. Scott T. Ford, CEO and Co-founder stated, &#8220;We are off to a great start in 2025. Today we are reporting solid financial results for the first quarter, and we continue to make great strides towards our goal of becoming the premiere integrated strategic supplier to the pre-eminent coffee, tea, and energy brands around the world.&#8221; The company's stock fell around 14% over the past five days and <a href="https://www.benzinga.com/quote/WEST">has a 52-week low</a> of $5.28.</li>
<li>RSI Value: 27.3</li>
<li>WEST Price Action: Shares of Westrock Coffee fell 5.6% to close at $5.96 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623">WEST stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="927" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040202/image-324.png" alt="" class="wp-image-957676" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040202/image-324.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040202/image-324-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040202/image-324-768x702.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">22nd Century Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, 22nd Century Group announced a 1-for-23 reverse stock split. The company's stock fell around 57% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/XXII">low of $6.28</a>.</li>
<li>RSI Value: 14.9</li>
<li>XXII Ltd Price Action: Shares of 22nd Century Group dipped 13.9% to close at $8.72 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623">XXII shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="865" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040254/image-325.png" alt="" class="wp-image-957679" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040254/image-325.png 865w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040254/image-325-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23040254/image-325-768x746.png 768w" sizes="(max-width: 865px) 100vw, 865px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

WEST

XXII

Top 3 Risk Off Stocks That Could Blast Off This Month

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients
Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed overall response (ORR) in CNS evaluable disease patients by BICR in overall cohort
Enrollment of first patient in a randomized, global pivotal Phase 3 (ALPACCA) study in first-line PACC patients expected in the second half of 2025
ArriVent to host virtual webinar today at 8 am ET
NEWTOWN SQUARE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced encouraging additional follow up proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations and a clinical development update for the firmonertinib program for the treatment of EGFR PACC mutant NSCLC. ArriVent plans to host a virtual webinar today June 23, 2025 at 8 am ET.

AVBP

ArriVent BioPharma Announces Additional Follow Up Proof-Of-Concept Data From Randomized Global Phase 1b FURTHER Trial For First-Line Firmonertinib Monotherapy In Patients With NSCLC Harboring EGFR PACC Mutations And Clinical Development Update For Firmonertinib Program

VOXR

Vox Announces Horseshoe Lights Project Advancement As Melody Gold Secures Licence To Process 500,000 Tonnes Of Gold Surface Materials

IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, today announced its participation in Quantum Korea 2025, taking place June 24–26 at the aT Center in Seoul. As part of its ongoing commitment to quantum education and ecosystem development, IonQ will also collaborate with Sungkyunkwan University to support a quantum hackathon aimed at fostering the next generation of quantum talent in South Korea.
IonQ Chief Marketing Officer Margaret Arakawa and Chief Revenue Officer Rima Alameddine are scheduled to present the company's updated technology and business roadmap following the recent acquisitions of Oxford Ionics and Lightsynq, and a majority stake in ID Quantique (IDQ). The exhibit floor presentation entitled "Exploring Quantum" is scheduled for Thursday, June 26, 2025 at 2:15 pm local time. IonQ will also demonstrate the IDQ Solteris Network Appliance, part of IDQ's Quantum Safe Ecosystem, designed to upgrade network infrastructure with quantum-safe encryption.
This year marks IonQ's third consecutive sponsorship of Quantum Korea, a leading conference organized by South Korea's Ministry of Science and ICT that explores global trends in quantum innovations. IonQ executives will participate in key sessions, presenting updates on the company's technology roadmap and highlighting collaborations with South Korean partners.
"Global partnerships have been fundamental to IonQ's growth, and our collaborations in South Korea are among the most impactful," said Niccolo de Masi, CEO of IonQ. "We're proud to contribute to the vibrant quantum ecosystem in South Korea and to support initiatives that cultivate the next generation of quantum innovators."
IonQ's sponsorship of Quantum Korea continues its ongoing support of South Korea's quantum initiatives. The company has contributed to Korea's National Quantum Strategy and supported multiple quantum hackathons and academic initiatives. Most recently, IonQ signed agreements with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionq.com%2Fnews%2Fionq-and-seoul-national-universitys-center-for-quantum-information-science&amp;esheet=54280096&amp;newsitemid=20250623062556&amp;lan=en-US&amp;anchor=Seoul+National+University&amp;index=1&amp;md5=2175dbae591ca2df517e91e77aac1bd4">Seoul National University</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.ionq.com%2Fnews%2Fnews-details%2F2021%2FIonQ-and-South-Koreas-Q-Center-Announce-Three-Year-Quantum-Alliance%2Fdefault.aspx&amp;esheet=54280096&amp;newsitemid=20250623062556&amp;lan=en-US&amp;anchor=Sungkyunkwan+University&amp;index=2&amp;md5=34753e2d03e8a3e7579aa2e2925f4ccf">Sungkyunkwan University</a> to support quantum research and workforce development. IonQ also signed a memorandum of understanding (MoU) with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionq.com%2Fnews%2Fionq-and-busan-metropolitan-city-sign-memorandum-of-understanding-to-drive&amp;esheet=54280096&amp;newsitemid=20250623062556&amp;lan=en-US&amp;anchor=Busan+Metropolitan+City&amp;index=3&amp;md5=37f06ce1dca771a329464130ed1dac0e">Busan Metropolitan City</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionq.com%2Fnews%2Fionq-signs-mou-with-intellian-deepening-its-commitment-to-advancing-south&amp;esheet=54280096&amp;newsitemid=20250623062556&amp;lan=en-US&amp;anchor=Intellian&amp;index=4&amp;md5=3dca0177498780fbfe0345927c791204">Intellian</a>, and the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionq.com%2Fnews%2Fionq-signs-mou-with-kisti-to-accelerate-south-koreas-role-in-the-global&amp;esheet=54280096&amp;newsitemid=20250623062556&amp;lan=en-US&amp;anchor=Korea+Institute+of+Science+and+Technology+Information&amp;index=5&amp;md5=b7ce8d827c990d53e90e20f3e7d49c23">Korea Institute of Science and Technology Information</a> (KISTI), with the intent to integrate IonQ's quantum technology into South Korea's high-performance computing infrastructure and support talent development initiatives. IonQ also announced plans to enter into a global quantum strategic partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionq.com%2Fnews%2Fionq-to-acquire-id-quantique-enter-into-strategic-partnership-with-sk&amp;esheet=54280096&amp;newsitemid=20250623062556&amp;lan=en-US&amp;anchor=SK+Telecom&amp;index=6&amp;md5=db55636d344893481fd7c5212ac51f9b">SK Telecom</a>, South Korea's largest wireless telecommunications operator.
Conference attendees can meet IonQ representatives at Booth #B-07 where they can learn more about the company's roadmap, and its latest quantum networking innovations.

IONQ

IonQ Showcases Quantum Tech and Talent Push in South Korea, Highlights Roadmap at Quantum Korea 2025

Keybanc analyst Sangita Jain downgrades KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) from Overweight to Sector Weight.

Keybanc Downgrades KBR to Sector Weight

JP Morgan analyst Michael Mueller downgrades Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Overweight to Neutral and maintains the price target from $108 to $108.

JP Morgan Downgrades Federal Realty Investment to Neutral, Maintains Price Target to $108

Rayonier Advanced Materials Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) (the "Company"), the global leader in High Purity Cellulose, and Verso Energy today announced the signing of a new Memorandum of Understanding (MoU) to deepen their strategic collaboration. The agreement represents a major step forward in evaluating the development of a breakthrough facility in Jesup, Georgia, to produce electro Sustainable Aviation Fuel (e-SAF) and valorize biogenic carbon dioxide from RYAM's manufacturing operations.
The MoU includes the formation of a joint steering committee, outlines an exclusivity period for project evaluation, and anticipates the negotiation of definitive agreements including a CO₂ supply contract. A feasibility study is already underway to assess the technical, economic, and environmental dimensions of the proposed projects, with a final investment decision expected in the next 18 to 24 months.
 &nbsp;

RYAM

Rayonier Advanced Materials And Verso Energy Sign MoU To Explore e-SAF Production In Georgia

Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its "Anatomy of Progress" nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following <a href="https://www.globenewswire.com/Tracker?data=5eOHSwvLkgeF9fmJc1mqPu2Vc7hnAXNpCITSFx3zn3_09TQcbUph0jmCjh278ECHOfmM16_zEfkM_hEnRKk6bcFfKXyD8vWWTH06_RN0d-0=">link</a>.
Skye Video Series: "Anatomy of Progress"
In this four-part video series highlighted below, Skye discusses unmet needs in the obesity therapeutic space, advantages and benefits of its peripheral CB1-receptor-targeting antibody, which is designed to support healthy weight loss, and development progress of this novel CB1-inhibiting molecule.
Skye's Chief Executive Officer, Punit Dhillon, commented on the important mechanistic advantages of nimacimab versus other CB1 inhibitors highlighted in this video update series: "Obesity isn't just a public health crisis, it's a biologically defended state, one that resists traditional treatments requiring smarter and safer interventions.
"At Skye, we're developing nimacimab, a CB1 antibody that targets receptors in the periphery, while remaining greater than 99% excluded from the brain. Unlike the small molecule CB1 inhibitors currently in development, nimacimab's differentiating peripheral restriction has the potential to demonstrate the same weight loss and metabolic benefits previously seen in clinical trials by first-generation CB1 inhibitors, without the significant neuropsychiatric liabilities that continue to plague its small molecule counterparts. So nimacimab is not just another anti-obesity drug, it represents a new frontier in how we think about fat metabolism, safety and long-term care."
The Anatomy of Progress video series is comprised of:
<ul>
<li>Overview – Highlights Skye's positioning and progress in the obesity landscape, noting the differentiation of its allosteric modulating antibody. &nbsp;</li>
<li>Chapter 1: Nimacimab – A Differentiated CB1 Inhibitor for Obesity – A review of Skye's highly peripherally-restricted CB1 inhibitor and its potential advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data. &nbsp;</li>
<li>Chapter 2: Nimacimab in the Clinic – Reviews Skye's current clinical activity and near-term Phase 2a clinical data readouts. &nbsp;</li>
<li>Chapter 3: Market Opportunity for Nimacimab – Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with nimacimab's target product profile. &nbsp;</li>
</ul>

SKYE

Skye Bioscience Showcases Anti-Obesity Drug Nimacimab at ADA Conference, Highlights Safer CB1 Approach

RFIL

RF Industries Secures $1.7M In Follow-On Orders For Integrated Small Cell Shrouds From Tier 1 Wireless Carrier

<ul>
<li>$2.2 million gross proceeds from warrant inducement transaction</li>
<li>$2.6 million gross proceeds from additional warrant exercises.</li>
</ul>

Health Care

Financing

Offerings

General

Innovative Eyewear Announced Immediate Exercise Of Certain Outstanding Warrants To Purchase 746,782 Shares At $2.60 Per Share

TD Securities analyst Andrew Charles reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Hold and maintains $90 price target.

Reiteration

SBUX

TD Securities Reiterates Hold on Starbucks, Maintains $90 Price Target

Press Releases

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

Legal

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals Announces Leadership Changes

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

Contracts

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Comments

Conduit Pharmaceuticals

Noticias

Últimas noticias sobre Conduit Pharmaceuticals (NASDAQ:CDT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL